Key facts
- Areteia Therapeutics’s last known valuation is $1.3B (Feb 2024).
- It has raised $425.0M across 2 recorded rounds; the latest was Early Stage VC (Series A1) ($425.0M) in Feb 2024.
- Notable investors include Viking Global Investors, GV, ARCH Venture Partners, Marshall Wace, Maverick Capital — 11 tracked in total.
- Areteia Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Feb 2025 ($360.0M sold to 16 investors).
- Status: Out of Business.
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Areteia Therapeutics
Funding rounds
2 roundsAbout Areteia Therapeutics
Developer of an oral medication intended to treat eosinophilic asthma. The company's platform is focused on developing an oral drug that inhibits eosinophil maturation, showing potential to reduce inflammation and alleviate symptoms of severe asthma, enabling asthma patients to manage their condition more effectively while offering a more accessible alternative to injectable therapies.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Chapel Hill, NC, United States
- Founded
- 2022
- Employees
- 35
- Website
- areteiatx.com/
- Ownership
- Out of Business
Areteia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Areteia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Areteia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.